WHO Guideline On Control And Elimination Of Human Schistosomiasis.pdf

# WHO Guideline on Control and Elimination of Human Schistosomiasis

## Summary

This World Health Organization (WHO) guideline provides evidence-based recommendations for the control and elimination of human schistosomiasis, a significant global health problem caused by parasitic worms. The document offers a comprehensive strategy to combat this disease, focusing on preventive chemotherapy with praziquantel as a key intervention.

Key Points:

- Assessing Conflicts of Interest: The guideline ensures transparency by declaring no conflicts of interest.
- Development Methodology: It employs a structured approach, including rating evidence certainty, applying an evidence-to-decision framework, and utilizing systematic reviews to support recommendations.
- Schistosomiasis Background: Schistosomiasis affects millions worldwide, with varying epidemiological patterns. Control and elimination strategies involve mass drug administration (MDA) and improved access to clean water and sanitation.
- Preventive Chemotherapy Recommendations:
- Based on prevalence of infection: The guideline suggests implementing preventive chemotherapy when the prevalence of schistosomiasis exceeds a certain threshold, specific for different age groups.
- Optimal Prevalence Threshold: For children aged 2–14 years, MDA is recommended at a prevalence of ≥5%. For adolescents and adults, a higher threshold of ≥10% is suggested.
- Praziquantel Administration: The dosage is set at 40 mg/kg body weight, administered once annually for areas with high transmission.
- Rationale: The recommendations aim to reduce schistosomiasis morbidity by targeting key age groups and ensuring optimal drug efficacy through regular administration.